AIVEN
29.11.2022 09:02:41 CET | Business Wire | Press release
Aiven, the open source cloud data platform company, has announced several key senior leadership appointments who collectively are focused on helping deliver the company’s commitment to democratising access to the best open source technologies while reducing the environmental impact of cloud services.
These strategic new leadership roles span operations and strategy, product marketing, developer relations, and product management and include
- Katariina Korhonen, Vice President of Strategy and Operations
- Amy Krishnamohan, Vice President of Product Marketing
- Ian Massingham, Vice President of Developer Relations and Community
- Jonah Kowall, Vice President of Product Management
Oskari Saarenmaa, CEO and Co-founder at Aiven, comments on the appointments. “Aiven’s mission is to make developers’ lives better, by helping them build more sophisticated applications accessible to all. When starting Aiven, our goal was to build the company that we wanted to work for. Today we are delighted to be welcoming such a talented group to our leadership team and our wider Aiven community. Our ability to attract the best talent, while also supporting the career growth of our people continues to be instrumental in helping us develop new platform capabilities that bring us closer towards our goal of building more sustainable applications in the cloud.”
Katariina Korhonen has been appointed Vice President of Strategy and Operations to Aiven's Executive Leadership team. Katariina works closely with other senior executives and the board of directors and is focusing on building out Aiven’s corporate, operations, and sustainability strategy globally. Prior to her new role, Katariina spent the last six years in various executive roles at Smartly.
Amy Krishnamohan has also joined as Vice President of Product Marketing with the responsibility for Aiven’s product marketing direction and strategy, and nurturing and engaging with key stakeholders such as analysts, industry thought leaders, and strategic customers to increase the market awareness of Aiven. A Masters alumna of Carnegie Mellon University, Amy has gained diverse experience across product marketing and marketing strategy where she managed open-source database projects and other cloud-native databases. Prior to joining Aiven, she led product marketing strategies from major database companies such as MariaDB and Google Cloud.
Aiven also welcomes Ian Massingham as the company’s Vice President of Developer Relations and Community focusing on further building Aiven’s relationship with the developer community and ensuring that our programs align with our mission of making developers’ lives better. Prior to joining Aiven, Ian led the Developer Relations & Community team at MongoDB. Before that, he played an integral role in establishing and scaling the evangelism and developer relations function at AWS and led Worldwide Solutions Architecture for Startup customers for the final 18 months of his tenure at AWS.
Jonah Kowall has also joined as Aiven’s new Vice President of Product Management. In his role, Jonah will lead and execute the product strategy and head the product team responsible for platform enhancements to support ongoing growth in Aiven’s customer base. Previously a Chief Technology Officer at Logz.io and several other startups, Jonah’s background includes being a Research VP at Gartner and a regular contributor and maintainer of the Open Source Jaeger and OpenTelemetry projects. Jonah joins Aiven and brings with him a wealth of knowledge on all things “observability”.
This latest announcement of senior leadership expansion closely follows the appointment of Olivier van Grembergen as Regional Vice President (RVP) of Aiven Asia Pacific (APAC), announced earlier in October to drive continued growth in the region.
To learn more about Aiven, please visit https://aiven.io/
Free Trial https://console.aiven.io/signup
About Aiven
Headquartered in Helsinki and with hubs in Berlin, Boston, Paris, Singapore, Sydney, Tokyo, and Toronto, Aiven provides managed open source data technologies, like PostgreSQL, Apache Kafka and OpenSearch, on all major clouds. Through Aiven, developers can do what they do best: create applications. Meanwhile, Aiven does what they do best: manage cloud data infrastructure. Aiven enables customers to drive business results from open source that trigger true transformations far beyond their own backyard. Most recently, Aiven achieved a $3B valuation and has now raised $420M total funding backed by its investors Atomico, Earlybird, Eurazeo, IVP, Lifeline, Salesforce Ventures, and World Innovation Lab.
To learn more about Aiven, visit aiven.io and follow @aiven_io on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
